VistaGen Therapeutics

VTGN

Valor de mercado US$ 8,88 mi

Options traders are buying the dip in two stocks this morning, with Meta Platforms (NASDAQ:META) and Vistagen Therapeutics (NASDAQ:VTGN) drawing bullish options activity as both equities trade lower.

Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company's website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orleans.

Vistagen Inc. (NASDAQ:VTGN) surged on Wednesday after preliminary findings from the open-label extension portion of its PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for acute social anxiety disorder.

Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months

Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement Efficacy signals and responder analyses provide additional supportive evidence for discussion with the FDA regarding fasedienol registrational pathway SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of its exploratory Phase 2 repeat dose study evaluating fasedienol nasal spray in adult subjects with social anxiety disorder.

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study population.